CellSight is a synergistic cross-disciplinary team of investigators pursuing cutting-edge research and working in a highly collaborative manner with basic researchers and clinicians with a common vision: to develop novel stem cell-based therapeutics to save and restore sight in patients with blinding diseases.
CellSight integrates several independent research groups that have come together as a unified team to find solutions to ocular diseases. In a concerted effort, the investigators at CellSight work with the clinicians at the Sue Anschutz-Rodgers Eye Center and the Gates Institute with a goal of translating innovative treatments from the laboratory bench to the bed side.
Our ongoing collaborative work with investigators from the Gates Institute and the Skaggs School of Pharmacy position us particularly well for succeeding in the discovery of new therapies for eye diseases and in translating them from the lab to the clinic. Investigators at the Skaggs School of Pharmacy contribute with their expertise in drug development and testing. The Gates Institute, with the Gates Biomanufacturing Facility, brings the expertise and capability to produce our stem cell and drug-based discoveries at the scale and quality required to initiate clinical trials.
Since 2017, we've been granted one domestic patent, and submitted six additional patent applications.
We've received 20 grants and awards, including nine at the federal level, one at the state level, one from industry, and four from foundations.
We have 11 partnerships, including seven academic and four industry partnerships.
We've authored more than 30 publications since 2017.